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Letters
Epi-inositol is ineffective in
Porsolt Forced Swim Test
model of depression
The six-carbon polyol inositol is a uniquely versatile
compound in biology. Myo-inositol is the major naturally
occurring isomer of nine possible inositol isomers and is
critical for the phosphoinositide (PI) cycle as a substrate
for PI synthase (Berridge and Irvine 1989). Benjamins and
Agranoff (1969) reported that epi-inositol is not a substrate
for PI synthase, but a number of experiments suggest that
epi-inositol might affect the PI cycle. Like myo-inositol,
epi-inositol was shown to reverse Li-pilocarpine seizures
(Williams and Jope 1995), strongly suggesting that epi-
inositol could enter the PI cycle. Furthermore, accumulation
of [3H]-cytidine monophosphate phosphatidate (CMP-PA)
in Chinese hamster ovary (CHO) cells during Li treatment
is reversible with myo-inositol, and Richards and Belmaker
(1996) found that epi-inositol was about 30%–40% as active
as myo-inositol in reversing such accumulation. Myo-
inositol has been found to have antidepressant and
antianxiety effects in animal models (Einat and Belmaker
2001) and in controlled studies in patients (Levine 1997).
Recently, Einat et al (1998) studied epi-inositol in the
elevated plus maze model of rat anxiety and surprisingly
found it much more active than myo-inositol.
In this report, we explored the effects of epi-inositol in
the Porsolt Forced Swim Test model of depression (FST)
and have attempted to replicate our previous results in the
Elevated Plus Maze.
For the FST, rats (n = 10/group) were tested with two
exposures to a water tank spaced 24 hours apart. Epi-inositol
treatment (5 g/kg diluted in deionized water to 20 mL/kg)
consisted of two injections, the first immediately after the
first exposure to the water tank and the second 5 hours prior
to the second exposure (the test session). This dose and
schedule of injections was chosen because it was
demonstrated to be effective in this model with myo-inositol
(Einat et al 1999, 2001). The Elevated Plus-Maze model
for anxiety study was designed to replicate our previously
reported experiment (Einat et al 1998) and included 3 groups
(n = 10/group) receiving chronic (11 days) daily intra-
peritoneal injections at a dose of 1.2 g/kg myo-inositol, epi-
inositol, and control solutions. Five to six hours after the
last injection, animals were tested in an elevated plus-maze.
A student’s t-test was used to analyze the FST results. Since
data were not homogenous (Levene test: F(2,26) = 3.8,
p < 0.04), the Plus-Maze measures were analyzed using a
Kruskall-Wallis nonparametric analysis of variance
(ANOVA) followed by similar post-hoc comparisons of
open/closed arms entries and time ratio.
Epi-inositol treatment did not affect immobility
(t(18) = 0.4, NS), swimming (t(18) = 0.84, NS), or struggle
time (t(18) = 0.24, NS) in the FST. As previously reported,
myo-inositol had an anxiolytic-like effect in the plus-
maze model as demonstrated by significant increase in
open/closed arms entries ratio (Kruskall-Wallis ANOVA,
χ2(2) = 7.2, p < 0.03, post hoc tests myo-inositol different
than control) and a similar trend for increase in open/closed
arms time ratio (χ2(2) = 5.6, p = 0.06). However, in contrast
with our previous findings, epi-inositol had no anxiolytic
effects in the elevated plus-maze model.
Epi-inositol was not active in the FST, and the previous
finding that epi-inositol is more effective than myo-inositol
in the elevated plus maze model of anxiety was not
replicated. Effects of myo-inositol in the FST have been
shown to be mediated by the serotonergic system,
specifically via 5-HT2A/C receptors (Einat et al 2001). Epi-
inositol is not a substrate for PI synthase, is not incorporated
into phosphatidylinositol, and does not enter into the PI cycle
second messenger system (Benjamins and Agranoff 1969).
The present finding therefore supports the hypothesis that
myo-inositol’s antidepressant and anxiolytic effectiveness
is based on its ability to affect the PI cycle activity.
Epi-inositol, similar to myo-inositol, was active in the
reversing of biochemical and behavioral effects of lithium
action (Godfrey 1989; Patishi et al 1996), and in yeast, epi-
inositol was shown to affect the expression of genes involved
in the metabolism of myo-inositol (Shaldubina et al 2002).
Therefore, the effect of epi-inositol, which is not
incorporated into the PI cycle, in biochemical and behavioral
models of lithium action could be explained by an epi-
inositol effect on myo-inositol metabolism at the level of
gene expression. However, as demonstrated by the present
results, epi-inositol may not be enough to independently
induce behavioral change in standard models of depression
or anxiety at the same design where myo-inositol induces a
clear and replicable behavioral change.
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